Abbott Laboratories Corporation

Kyowa Hakko Kogyo Co., Ltd.

Ryo Okachi

Takashi Nara

Isao Kawamoto

Kunikatsu Shirahata

Mitsuyoshi Yamamoto

Tomoyasu Sato

Takao Iida

Shinzo Ishii

Seigo Takasawa

Masahiro Sugimoto

Seiji Sato

Atsuko Morikawa

Masaji Kasai

Hiroshi Kase

Junichi Shimada

Moriyuki Sato

Yasuki Mori

Tetsuo Oka

Kenichi Mochida

Takehiro Ogasa

Kiyoshi Nakayama

Kiyoshi Sato

Yoshiaki Shimizu

Hiroshi Sano

Satoshi Omura

Akira Karasawa

Tadashi Hirata

Katsuichi Shuto

Keiichi Takahashi

Kinya Yamashita

Isao Matsubara

Toshiro Koguchi

Takashi Deguchi

Masayuki Yamato

Tadahi Hirata

Isao Maisubara

Carbacephem and cephem compounds represented by the formula: ##STR1## [Wherein X is S or CH.sub.2 ; n is an integer of 1 to 5; R.sub.1 is an unsubstituted or substituted heterocyclic group (where the heterocyclic group is a 5- or 6-membered heterocyclic group having 1 to 4 of O, S and N); R.sub.2 is a group represented by the formula: ##STR2## (where R.sub.4 is an unsubstituted or substituted phenyl or 2-aminothiazolyl) or a group represented by the formula: ##STR3## (where R.sub.5 is an unsubstituted or substituted lower alkyl); R.sub.3 is hydrogen, an alkali metal, an alkaline earth metal, an organic ammonium group or an ester residue, and R.sub.1 may be a quaternary ammonium group, where --CO.sub.2 R.sub.3 represents --CO.sub.2.sup.- ] have strong antibacterial activity against Gram-positive and Gram-negative bacteria, and are useful for treating various infections.

3-heteroaralkylthio carbacephem compounds and antibacterial

Disclosed is a novel physiologically active substance, K-26, a process for preparation thereof and a pharmaceutical composition containing the same. The composition of matter, K-26, is useful as a hypotensive agent.

Novel physiologically active substances K-26, a process for preparation

Carbacephem compounds represented by the formula: ##STR1## [wherein R.sub.1 is a lower alkylsulfonyloxy, unsubstituted or substituted arylsulfonyloxy, azido, cyano, carbamoyloxy, unsubstituted or substituted heterocyclic thio ('heterocyclic' means a 5- or 6-membered heterocyclic group having 1 to 4 O, S or N atoms), unsubstituted or substituted lower alkylthio, or unsubstituted or substituted arylthio group; R.sub.2 and R.sub.3 are groups frequently used in the cephalosporin chemistry] have strong antibacterial activity against Gram-positive and Gram-negative bacteria, and are useful for curing various infections.

3-substituted carbacepem compounds having antibacterial effect

3, 3', 4'-Tri-O-acylspiramycin I represented by the formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different groups, and at least one of the groups is a straight or branched chain alkylcarbonyl group represented by --COC.sub.m H.sub.2m+1 wherein m is an integer of 2-4 and the other group(s) are straight or branched chain alkylcarbonyl group(s) represented by --COC.sub.n H.sub.2n+1 wherein n is an integer of 1-4, and its pharmacologically acceptable acid addition salts.

3, 3', 4'-Tri-O-acylspiramycin I

Disclosed is a novel physiologically active substance K-4 which has a hypotensive activity, a process production thereof and a pharmaceutical composition containing the same.

Novel physiologically active substance K-4, a process for preparation

The antibacterial compounds 7-deazaadenosine and 7-deazinosine are produced by fermentation of a new microorganism of the genus Micromonospora. At least one of the active substances is isolated from the culture medium.

Process for the production of 7-deazaadenosine and 7-deazainosine

New antibacterial compounds, XK-62-3 and XK-62-4, are produced by fermentation of microorganisms belonging to the genus Micromonospora. The compounds are accumulated in the culture liquor and are isolated therefrom.

Antibiotics XK-62-3 and XK-62-4 and process for production thereof

New antibiotic compounds, Fortimicin factors D and KE are produced by fermentation of microorganisms belonging to the genus Micromonospora. The antibiotic compounds are accumulated in the culture liquor and are isolated therefrom. A semisynthetic method of producing Fortimicin KE utilizing Fortimicin D is also disclosed.

Fortimicin factors D and KE compounds

New antibiotic compounds, Fortimicin factors KF and KG are produced by fermentation of microorganisms belonging to the genus Micromonospora. The antibiotic compounds are accumulated in the culture liquor and are isolated therefrom.

Fortimicin factors KF and KG and process for production thereof

A novel antibacterial compound, XK-99, is produced by fermentation of an organism belonging to the genus Micromonospora. The compound is isolated from the microbial cells and culture liquor.

Antibiotic XK-99 and process for production thereof

Process for producing fortimicin factors

A new antibiotic, Fortimicin C, is produced by fermentation of a microorganism belonging to the genus Micromonospora. The antibiotic is accumulated in the culture medium and is isolated therefrom.

Fortimicin C and process for production thereof

The antibiotic XK-62-2 is produced by fermentation of microorganisms belonging to the genus Micromonospora. The antibiotic is accumulated in the culture liquor and is isolated therefrom.

Antibiotic XK-62-2 and process for production thereof

Growing community of inventors

Machida, Japan

Ryo Okachi